ProKidney to Present at the Jefferies Cell and Genetic Medicine Summit
WINSTON-SALEM, N.C., Sept. 23, 2022 (GLOBE NEWSWIRE) — ProKidney Corp. (Nasdaq:PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that Dr. Tim Bertram, Chief Executive Officer of ProKidney, will present a corporate overview at the Jefferies Cell and Genetic Medicine Summit at 1:30 p.m. ET on Thursday, September 29, 2022, in New York, NY.
Related news for (PROK)
- ProKidney Reports First Quarter 2025 Financial Results and Business Highlights
- Breaking News: MoBot’s Latest Update as of 04/15/25 09:00 AM
- ProKidney Reports Full Year 2024 Financial Results and Business Highlights
- prokidney announces strategic updates to its phase 3 program to accelerate rilparencel’s registrational path to potential approval in the u.s.
- ProKidney Appoints Nikhil Pereira-Kamath, MBA, as Chief Business Officer